We have compiled a list of manufacturers, distributors, product information, reference prices, and rankings for Model mouse.
ipros is IPROS GMS ・ IPROS One of the largest technical database sites in Japan that collects information on.

Model mouse - List of Manufacturers, Suppliers, Companies and Products

Model mouse Product List

1～5 item / All 5 items

Displayed results
Human-type model animal

Human-type model animal

We will create mice and rats with drug metabolism similar to that of humans!

We have created human-like drug metabolism model mice and rats equipped with artificial chromosome vectors carrying human drug metabolism-related genes. By administering new drugs, we can predict safety for humans, leading to accelerated pharmaceutical development and reduced costs. 【Features】 ■ Improved prediction of safety for humans ■ Accelerated pharmaceutical development and increased success rates ■ Lower costs for new drug development and reduced national healthcare burden *For more details, please refer to the catalog or feel free to contact us.

  • Other experimental equipment

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Ultra First (3 weeks) NASH screening mouse model

Ultra First (3 weeks) NASH screening mouse model

Physiogenex has developed a method for NASH screening that can be implemented in three weeks. The control drugs are ezetimibe and liraglutide.

A test system has been developed by Physiogenex using a unique method (using cyclodextrin, as described later) that allows for the extremely rapid induction of NASH within just three weeks. This model uses 8-week-old male mice and measures parameters such as ALT, AST, liver weight as a percentage of body weight, total cholesterol, triglycerides, and fatty acids, all of which increase within just three weeks (at 11 weeks of age). It also shows an increase in the NAS score (indicators: steatosis, inflammation, fibrosis, ballooning, total score) and significant liver inflammation and fibrosis. Treatment with ezetimibe (5 mg/kg) for two weeks results in a decrease in plasma total cholesterol and liver fat, a reduction in gene expression related to inflammation and fibrosis, and a lower overall NAFLD score due to decreased liver inflammation. Similarly, treatment with liraglutide for two weeks also shows a reduction in body weight and liver weight, as well as a lower overall NAS score due to decreased liver inflammation. For more details, please contact us. *Inquiries can also be made through our website. We will respond promptly. (Search for "Clea Japan" at http://www.clea-japan.com/)

  • Other Contract Life Science Specialization

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
"Arthritis model" CIA model CAIA model

"Arthritis model" CIA model CAIA model

Stress-free rearing under advanced microbiological control is essential for the stability of the system. Our company is capable of producing high-quality autoimmune disease models!

We would like to introduce the "Arthritis Model" that we handle. In the production of autoimmune disease models, stress-free breeding under advanced microbiological control is essential for system stability. Furthermore, providing appropriate care for symptoms is also important for maintaining the health of the mice. Our company is capable of producing high-quality autoimmune disease models through advanced breeding management techniques and meticulous attention to the disease state. [Features] ■ Advanced breeding management techniques ■ Meticulous attention to the disease state ■ Capability to produce high-quality autoimmune disease models *For more details, please refer to the PDF materials or feel free to contact us.

  • Animal cells

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Graft-versus-host disease (GvHD)

Graft-versus-host disease (GvHD)

We will introduce the transplantation and anatomical results of the "acute GvHD model" and "chronic GvHD model."

We would like to introduce the production of model mice/rats for "graft-versus-host disease (GvHD)" that we are conducting. The "acute GvHD model," which is a dangerous complication in bone marrow transplantation, is created by transplanting donor spleen cells into recipient mice, while the "chronic GvHD model" induces symptoms similar to lupus nephritis. Please feel free to contact us for more details. 【Model Examples】 ■ Acute GvHD Model ■ Chronic GvHD Model *For more information, please refer to the PDF document or feel free to contact us.

  • Animal cells

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Diet-induced NASH mouse model

Diet-induced NASH mouse model

Physiogenex's proprietary diet-induced (DIN) NASH mouse model. Evaluation of NASH drug efficacy in an obese and insulin-resistant environment.

The Physiogenex independently developed diet-induced NASH mouse model involves feeding a high-fat, high-cholesterol diet, along with the addition of fructose to drinking water. This induces severe liver damage, obesity, and insulin resistance. As a result, liver fat and hepatocyte ballooning appear by the 16th week of feeding, and severe liver complications (inflammation and fibrosis) develop by 25 weeks of age. Additionally, the administration of the FXR agonist obeticholic acid, which is related to NASH, results in observed reductions in obesity, insulin resistance, fatty liver, and ballooning at both 16 and 25 weeks of age. This experimental system allows for the efficacy evaluation of drugs using obeticholic acid as a control, set against a background of obesity and insulin resistance that resembles the histopathological features of human NASH. Furthermore, there are efficacy evaluation data and academic papers (PDF) using Elafibranor (GFT505) as a control drug. For more details, please contact us. *Inquiries can also be made through our website. We will respond promptly. (Search for "Clea Japan" at http://www.clea-japan.com/)

  • Other Contract Life Science Specialization

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Related Categories of Model mouse

COPYRIGHT © 2001-2025 IPROS CORPORATION ALL RIGHTS RESERVED.